Clinical Trial Search

Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001

Primary: [11C]5-hydroxy-tryptophan Uptake in the Pancreas — 0.17; 0.21; 0.20; 0.23 % of injected dose — p=0.5875

Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43

Primary: Glucose Tolerance at 24 Weeks — 2; 4; 3; 4 Participants

Primary: Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39 — 7.4; 7.9; 7.8; 10.2 pmol/l

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Pancreatic and Liver Fat — 1.87; 6.57; 3.61; 5.85 percent

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Mean VMAT2 Functional Binding Capacity in the β Cells to 18 F-FP-DTBZ — 103; 38 unitless

Primary: Arginine-stimulated Insulin Secretion With and Without GLP-1 Blockade — 320.1; 243.4; 280; 251.2 pmol/L — p=< 0.05

Primary: Mean Blood Glucose Area Under the Curve (AUC 0-6h) — 2,096; 1,678 mmol*min/L

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Glucagon Response to Acute Hypoglycaemia — 1.33; 1.0; 1.33 pmol/L — p=1.0

Primary: Mean Plasma Glucose Level. — 149.666118; 162.574753 mg/dL

Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L

Primary: Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml) — 214; 149; 133; 188.5 μU/ml — p==0.1

Primary: Steady State Beta Cell Compensation — 3.01; 3.19 (nmol/L) adjusted for M/I — p=0.05

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24

Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05

Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale

Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL

Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min

Primary: Insulin Secretion — 56766 pmol/l * 90 minutes

Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001

Primary: The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation — 5 participants

Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl

Primary: Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months…

Primary: Postprandial Glucose Nadir — 57.1; 59.2; 47.1 mg/dL

Primary: Insulin Independence — 42; 45 percentage of participants